UK: Ova But Not Out: A Tale Of Patents And Parthenotes

Last Updated: 9 September 2014
Article by Beatriz San Martín and Hannah Smith-Willis

What constitutes a human embryo is important to determine the patentability of certain biotech inventions as under Article 6(2)(c) of the Directive on the Legal Protection of Biotechnological Inventions (98/44/EC), commonly referred to as the Biotech Directive, the use of human embryos for industrial and commercial purposes is excluded from patentability.  The meaning of 'human embryo' under the Biotech Directive, has already been considered by the Court of Justice of the European Union (CJEU) in Oliver Brüstle v Greenpeace (Case C-34/10), when the CJEU adopted a wide interpretation and held that any organism "capable of commencing the process of development of a human being" must be regarded as a human embryo and this included parthenotes (unfertilised ova/oocytes activated by chemical or electrical manipulation to initiate the process of cell division and development).

Whether parthenotes can constitute human embryos is currently being re-considered by the CJEU in Case C-364/13 International Stem Cell Corporation v Comptroller General of Patents in circumstances where such parthenotes are incapable of developing into human beings.  On 17 July 2014, Advocate General Cruz Villalón delivered his Opinion and concluded that parthenotes that are not able to develop into a human being and have not been genetically manipulated to acquire such capacity should not be considered 'human embryos' under the Biotech Directive.  This Opinion will be generally welcomed by the biotech industry and it is hoped that the CJEU will follow the decision of the AG.


The limitation on patentability of biotech related inventions is a controversial area.  Under the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPs), to which all WTO members are signatories, although patents must be available for any invention in all fields of technology, this is subject to the proviso that members can exclude from patentability inventions on ordre public and morality grounds.

In July 1998, following significant developments in the biotech sector and a 10 year debate in the EU over how best to encourage biotechnology innovation in Europe while addressing ethical concerns, the EU finally adopted the Biotech Directive to harmonise patentability of biotech inventions.  Article 6(1) of the Biotech Directive confirms that inventions whose commercial exploitation would be contrary to ordre public or morality are unpatentable.  Article 6(2) goes on to provide a non-exclusive list of what is considered to be unpatentable and this includes "uses of human embryos for industrial or commercial purposes". 

Equivalent exclusions to patentability were subsequently included in the European Patent Convention and the Implementing Regulations to the EPC which, although not EU legal instruments, are relevant in that all Member States are signatories and the prosecution of the majority of patents in Europe is managed by the European Patent Office (EPO).  Indeed, in the WARF Enlarged Board of Appeal decision of November 2008, the EPO held that under the EPC it is not possible to grant a patent for an invention which necessarily involves the use and destruction of human embryos.  The only exception to this were those inventions involving the use of pluripotent human embryonic stem cells (hESCs) (which can develop into some but not all cell types) and which could be generated by using cell lines which were publically available at the relevant filing date since destruction of human embryos to generate these cell lines was historical.

In Brüstle, the CJEU went one step further and held that inventions that required the destruction of human embryos, no matter when this may have occurred, are unpatentable. The case also for the first time attempted to define what is meant by a 'human embryo' for the purposes of Article 6(2)(c) of the Biotech Directive providing a wide interpretation which covered all of the early stages of human development and all other similar cells which have the capability of commencing the process of development of a human being, including parthenotes. 

ISC reference to the CJEU

In the current case, ISC sought two patents from the UK IPO: a method of producing pluripotent hESCs and corneal tissue derived from such cells from parthenogenetically-activated oocytes (GB0621068.6) and a method of isolating pluripotent hESCs from parthenogenetically-activated oocytes (GB0621069.4).  As these oocytes have not been fertilised the resulting parthenotes contain only half the amount of genetic material to that found in fertilised cells; they contain only maternally derived genetic material but lack paternal chromosomes.  Due to "genomic imprinting" some genes are only expressed in paternal rather than maternal DNA and are therefore repressed in parthenotes while other genes which would normally be repressed may be abnormally expressed.  As a consequence, parthenotes cannot develop into viable human beings.  Thus the cells of a parthenote are pluripotent (capable of differentiating into embryonic but not extra-embryonic tissues, for which paternal DNA is required) and not totipotent (capable of differentiating into all human cell types including extra-embryonic tissues).

Following the broad interpretation of a 'human embryo' in Brüstle, the UK IPO felt bound to refuse ISC's patent applications on the ground that the organisms produced by the inventions are "capable of commencing the process of development of a human being" and therefore excluded from patentability by the Biotech Directive. 

ISC appealed to the High Court [1]. It did not consider it necessary to refer the matter to the CJEU for a preliminary ruling as, in its view, it was acte clair because the key question following the CJEU decision in Brüstle was whether an organism is capable of commencing the process of development which leads to a human being.  ISC submitted that the Brüstle decision excluded parthenotes from patentability only to the extent that they are capable of giving rise to totipotent cells, each of which has the capacity to develop into a complete human being. 

The Comptroller General of Patents did not consider the matter acte clair as it was unclear whether the CJEU had in mind a test whereby commencing the process of development of a human being sufficed or whether it needed to be a process that was capable of leading to a viable human being.  Deputy Judge Henry Carr QC agreed that the matter was not clear and that it justified a further reference to the CJEU with the question:

"Are unfertilised human ova whose division and further development have been stimulated by parthenogenesis, and which, in contrast to fertilised ova, contain only pluripotent cells and are incapable of developing into human beings, included in the term "human embryos" in Article 6(2)(c) of Directive 98/44 on the Legal Protection of Biotechnological Inventions?".

On 29 April 2014, the CJEU held a hearing in which ISC, the UK, France, Sweden and the Commission made oral observations, having previously received written observations from each of them as well as from Poland and Portugal. 

The Opinion of the Advocate General

In answering the question, Advocate General Villalón highlighted the previous CJEU reference made in the Brüstle case.  He noted that the current reference is identical save that the ISC reference explicitly refers to unfertilised human ova containing only pluripotent cells which are incapable of developing into a human being.

Key to the Court's decision in Brüstle and therefore central to the interpretation of Article 6(2)(c) was the criterion of being "capable of commencing the process of development of a human being".  AG Villalón rejected the view that this refers simply to the commencement of the first steps of development but rather it is the inherent capacity to develop into a human being which is determinative.  In his view, the Court in Brüstle established a 'functional equivalence' between the inherent capacity of fertilised ova and parthenotes, which is now known to be scientifically inaccurate.

The AG considered the nature and extent of the list of prohibitions to patentability in Article 6(2). In particular he noted that the list should be regarded as a minimum 'no-go zone' for all Member States on which inventions should be considered unpatentable but it is non-exhaustive and merely illustrative as to which inventions would offend against ordre public or morality. Ultimately, however, a Member State could still decide to exclude parthenotes from patentability under Article 61 if the Member State in question decided that parthenotes offend their own standards of ordre public or morality.

The AG also dismissed the idea that a parthenote could offend Article 5 of the Biotech Directive, which excludes from patentability the human body at any stage of development or any 'elements isolated from the body'. He argued that parthenotes could not be classified as a human body or a stage of its formation; they were created from a technical process and Article 5 by itself does not prevent their patentability.

Observations were submitted to the CJEU in support of ISC's submissions that parthenotes should not be considered 'human embryos' in the sense of Article 6(2)(c) by France, Sweden, the UK, and the European Commission.  Portugal was also in support of ISC's submissions but emphasised the risk of parthenotes acquiring the ability to develop into a human being through additional manipulation and suggested it should be up to the national court to ensure this capacity does not exist for the patent at issue.  Poland, in contrast to all other submissions, argued that in the interest of safeguarding human dignity, the focus should be on the capacity to commence the process of development, regardless of whether that process is fundamentally ill-fated.

AG Villalón recognised that it may eventually be possible to genetically manipulate a parthenote so that it can develop into a human being.  In his conclusion, he therefore caveated the patentability of parthenotes with the stipulation that they are "not capable of developing into a human being and have not been genetically manipulated to acquire such capacity".


The exclusion from patentability of hESCs isolated from fertilised ova as well as the societal and ethical dilemmas it creates leaves an opening for cellular therapies based on alternative methods for obtaining stem cells. The use of parthenogenetic hESCs has huge potential to provide cells and tissue for developing new cellular therapies and for regenerative medicine, and are viewed as one of the most promising alternative sources of histocompatible (tissue-compatible)  cells.  In addition, hESCs derived from parthenogenetic embryos have the advantage over traditional methods of reprogramming somatic cells in terms of the cost and time required to produce clinical-grade cells.  Recently discovered alternatives such as umbilical cord blood could be a promising source of cells for use in blood-related diseases but questions exist over their effectiveness for establishing treatments for non-blood related diseases.  Research in parthenogenetic hESCs is still in its infancy but recent studies have shown promising applications, such as genetic screening in mammalian cells.

The Opinion is regarded by many, including the authors, as a sensible conclusion and would serve as a much needed carve-out to the Court's conclusions in Brüstle.  It will no doubt come as welcome news to biotech companies who develop cellular therapies; if the CJEU follows the Opinion, the increased ability to secure patent protection across the EU would remove much uncertainty for investors and encourage investment in the field. 


1 [2013] EWHC 807 (Ch)

Article first appeared in Intellectual Property Magazine - September edition

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Beatriz San Martín
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.